Should I buy or sell Sanara MedTech stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMTI shares. View SMTI analyst ratings or view top-rated stocks .

What is Sanara MedTech's stock price target for 2024?

1 Wall Street research analysts have issued 1-year price targets for Sanara MedTech's shares. Their SMTI share price targets range from $44.00 to $44.00. On average, they anticipate the company's stock price to reach $44.00 in the next year. This suggests a possible upside of 36.4% from the stock's current price. View analysts price targets for SMTI or view top-rated stocks among Wall Street analysts .

How have SMTI shares performed in 2024?

Sanara MedTech's stock was trading at $41.10 at the beginning of 2024. Since then, SMTI stock has decreased by 21.5% and is now trading at $32.25. View the best growth stocks for 2024 here .

When is Sanara MedTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SMTI earnings forecast .

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.09. The company had revenue of $5.82 million for the quarter. Sanara MedTech had a negative net margin of 6.62% and a negative trailing twelve-month return on equity of 11.12%. During the same quarter in the prior year, the business posted ($0.18) earnings per share.

What guidance has Sanara MedTech issued on next quarter's earnings?

Sanara MedTech updated its fourth quarter 2023 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $17.7 million-$17.7 million, compared to the consensus revenue estimate of $16.5 million.

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE) , Ovintiv (OVV) , SIG (SHI) , Zynerba Pharmaceuticals (ZYNE) , AbbVie (ABBV) , American Airlines Group (AAL) , Abbott Laboratories (ABT) , AC Immune (ACIU) and Applied Genetic Technologies (AGTC) .

How do I buy shares of Sanara MedTech?

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SMTI

Sanara MedTech (SMTI) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free SMTI Stock Alerts

$32.25

-1.27 (-3.79%)

(As of 04/15/2024 ET)

Compare

Today's Range: $32.05
▼
$33.92
50-Day Range: $32.25
▼
$40.20
52-Week Range: $26.06
▼
$49.87

Volume: 9,082 shs
Average Volume: 13,378 shs
Market Capitalization: $278.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.00

Get Sanara MedTech alerts:

Sanara MedTech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 36.4% Upside
$44.00 Price Target
Short Interest: Bearish
4.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.79 out of 5 stars

Medical Sector

654th out of 929 stocks

Surgical Appliances & Supplies Industry

15th out of 18 stocks

3.5

Analyst's Opinion

Consensus Rating
Sanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Sanara MedTech has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.13% of the float of Sanara MedTech has been sold short.
Short Interest Ratio / Days to Cover
Sanara MedTech has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Sanara MedTech has recently decreased by 0.97%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Sanara MedTech does not currently pay a dividend.
Dividend Growth
Sanara MedTech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SMTI.

3.3

News and Social Media Coverage

News Sentiment
Sanara MedTech has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sanara MedTech this week, compared to 1 article on an average week.
Search Interest
3 people have searched for SMTI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sanara MedTech insiders have not sold or bought any company stock.
Percentage Held by Insiders
55.20% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 8.10% of the stock of Sanara MedTech is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Sanara MedTech is -62.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sanara MedTech is -62.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sanara MedTech has a P/B Ratio of 6.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

He Is Giving Away Bitcoin

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Sanara MedTech Stock (NASDAQ:SMTI)

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

SMTI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SMTI Stock News Headlines

April 11, 2024 | investing.com

Sanara Medtech Inc (SMTI)

April 5, 2024 | markets.businessinsider.com

Sanara MedTech Names Jake Waldrop COO, Effective April 15; Stock Up In Pre-market

April 15, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

April 5, 2024 | globenewswire.com

Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer

March 29, 2024 | finance.yahoo.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q4 2023 Earnings Call Transcript

March 28, 2024 | seekingalpha.com

Sanara MedTech Inc. (SMTI) Q4 2023 Earnings Call Transcript

March 25, 2024 | investorplace.com

SMTI Stock Earnings: Sanara MedTech Beats EPS, Beats Revenue for Q4 2023

March 25, 2024 | finance.yahoo.com

Sanara MedTech Inc (SMTI) Reports Strong Sales Growth and Reduced Net Loss for Full Year 2023

April 15, 2024 | Crypto Swap Profits (Ad)

He Is Giving Away Bitcoin

March 25, 2024 | globenewswire.com

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

March 22, 2024 | benzinga.com

Sanara MedTech's Earnings: A Preview

March 13, 2024 | finance.yahoo.com

Investors in Sanara MedTech (NASDAQ:SMTI) have seen fantastic returns of 541% over the past five years

March 13, 2024 | globenewswire.com

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates

March 6, 2024 | benzinga.com

CGI Cellerate RX, LLC's Net Worth

February 23, 2024 | benzinga.com

Sanara MedTech Stock (NASDAQ:SMTI), Analyst Ratings, Price Targets, Predictions

February 22, 2024 | globenewswire.com

Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023

January 5, 2024 | finance.yahoo.com

Sanara MedTech Inc. (NASDAQ:SMTI) About To Shift From Loss To Profit

January 3, 2024 | msn.com

Sanara MedTech announces exclusive license agreement for patented collagen peptides

January 3, 2024 | markets.businessinsider.com

Sanara MedTech Inks Exclusive License Agreement With Tufts University

January 3, 2024 | finance.yahoo.com

Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides

December 4, 2023 | finance.yahoo.com

Sanara MedTech Inc.'s (NASDAQ:SMTI) top owners are retail investors with 32% stake, while 31% is held by insiders

November 30, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing

November 15, 2023 | finance.yahoo.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q3 2023 Earnings Call Transcript

November 13, 2023 | msn.com

Sanara MedTech GAAP EPS of -$0.13, revenue of $16M misses by $2.8M

November 13, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces Third Quarter 2023 Results

November 13, 2023 | finance.yahoo.com

Sanara MedTech Inc. Reports Record Sales in Q3 2023 with Narrowed Net Loss and Positive ...

November 12, 2023 | morningstar.com

Sanara MedTech Inc SMTI

See More Headlines

Receive SMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Current Symbol: NASDAQ:SMTI
CUSIP: N/A
CIK: 714256
Web: www.wndm.com
Phone: (817) 529-2300
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.00
High Stock Price Target: $44.00
Low Stock Price Target: $44.00
Potential Upside/Downside: +36.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,300,000.00
Net Margins: -6.62%
Pretax Margin: -6.83%
Return on Equity: -11.12%
Return on Assets: -7.11%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 1.38
Quick Ratio: 1.04

Sales & Book Value

Annual Sales: $64.99 million
Price / Sales: 4.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.22 per share
Price / Book: 6.18

Miscellaneous

Outstanding Shares: 8,623,000
Free Float: 3,863,000
Market Cap: $278.09 million
Optionable: Not Optionable
Beta: 1.57

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Ronald T. Nixon (Age 68)
Executive Chairman
Mr. Zachary B. Fleming (Age 49)
Chief Executive Officer
Comp: $593.64k
Mr. Michael D. McNeil (Age 59)
CFO & Corporate Secretary
Comp: $438.68k
Dr. Christopher A. Morrison FACHM (Age 54)
FAPWCA, FCCWS, M.D., President of Telehealth Services
Comp: $156k
Mr. Callon Nichols
Vice President of Corporate Operations
Mr. Bill Fitzgerald
Chief Compliance Officer
Ms. Tricia Matteson
Vice President of Marketing
Dr. Rebecca Erin Mcmahon (Age 39)
President of Research & Development
Mr. Seth Yon
President of Commercial

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SMTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Sanara MedTech stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMTI shares.
View SMTI analyst ratings or view top-rated stocks.
What is Sanara MedTech's stock price target for 2024?: 1 Wall Street research analysts have issued 1-year price targets for Sanara MedTech's shares. Their SMTI share price targets range from $44.00 to $44.00. On average, they anticipate the company's stock price to reach $44.00 in the next year. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for SMTI or view top-rated stocks among Wall Street analysts.
How have SMTI shares performed in 2024?: Sanara MedTech's stock was trading at $41.10 at the beginning of 2024. Since then, SMTI stock has decreased by 21.5% and is now trading at $32.25.
View the best growth stocks for 2024 here.
When is Sanara MedTech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SMTI earnings forecast.

How were Sanara MedTech's earnings last quarter?: Sanara MedTech Inc. (NASDAQ:SMTI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.09. The company had revenue of $5.82 million for the quarter. Sanara MedTech had a negative net margin of 6.62% and a negative trailing twelve-month return on equity of 11.12%. During the same quarter in the prior year, the business posted ($0.18) earnings per share.
What guidance has Sanara MedTech issued on next quarter's earnings?: Sanara MedTech updated its fourth quarter 2023 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $17.7 million-$17.7 million, compared to the consensus revenue estimate of $16.5 million.
What other stocks do shareholders of Sanara MedTech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), AC Immune (ACIU) and Applied Genetic Technologies (AGTC).
How do I buy shares of Sanara MedTech?: Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SMTI) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial